China’s Regulatory Reckoning: A New Model for Cell and Gene Therapy

As the world races to bring cell and gene therapies (CGTs) to patients, China has quietly built a regulatory and payment framework that diverges markedly from Western models—and may hold vital lessons for the entire field. A new study published in Clinical Pharmacology & Therapeautics offers a detailed comparison of how China and the United States are tackling the twin challenges of accelerating approval for these breakthrough treatments while managing their extraordinary costs.

Chinese scientists have found that while the US relies on a market-driven structure—early-stage regulatory acceleration paired with commercial insurance and Medicare pilots—China has taken a more cautious, government-led path. The Chinese model operates through three distinct regulatory phases, emphasizing “technology-first” rigor and careful risk control. On the payment side, it centers on prudent national medical insurance negotiations and local supplementary coverage, rather than market pricing.

Both countries, the study reveals, share common dilemmas: a persistent shortage of long-term evidence, the difficulty of adapting payment systems to one-time curative therapies, and profound regional inequalities in access. The authors propose targeted solutions—including risk-adapted hierarchical regulation, cross-border collaborative payment mechanisms, and greater industrial synergy—that could guide global policymaking. For nations watching China’s rapid biotech ascent, this analysis provides a rare, data-driven look at a system that is simultaneously cautious, ambitious, and increasingly influential on the world stage.

Why it matters:
As China’s CGT pipeline matures, its regulatory and payment experiments will influence global supply chains, pricing benchmarks, and clinical trial strategies. For pharmaceutical executives and health policymakers, understanding this evolving framework is no longer optional—it is a strategic necessity.

Source →